Deal Watch: BMS Licenses Bispecific TCR Candidate From Immatics

BioMarin teams with Skyline on gene therapies for cardiovascular disease. Myrtelle discloses licensing of gene therapy for Canavan disease from Pfizer earlier in 2021.

Deal Watch 2021

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.

Immatics N.V. and Bristol Myers Squibb Company entered into a license, development and commercialization agreement on 14 December...

More from Deal Watch

More from Deals